Literature DB >> 9756445

Photorefractive keratectomy using the summit SVS Apex laser with or without astigmatic keratotomy.

S S Shah1, M S Kapadia, D M Meisler, S E Wilson.   

Abstract

PURPOSE: The purpose of this study was to evaluate the results of myopic photorefractive keratectomy (PRK) with or without astigmatic keratotomy (AK) for different levels of intended correction by using the SVS Apex laser.
METHODS: This is a retrospective cohort study of 226 eyes that had PRK for myopia ranging from -1.0 to -7.6 diopters and 6 months of follow-up. In addition, 64 of these eyes had AK for naturally occurring or laser-induced astigmatism. Uncorrected visual acuity, spectacle-corrected visual acuity, and corneal topography with quantitative descriptors of surface regularity (SRI) and surface asymmetry (SAI) were used to monitor the results of PRK with or without AK.
RESULTS: At 6 months, 95.6% eyes had an uncorrected visual acuity of 20/40 or better, 90% eyes were within +/-1.0 diopter of emmetropia, and 3.1% eyes lost two lines of best-corrected vision. No eyes lost more than two lines of best-corrected vision. Mean refractive astigmatism was reduced, but mean SAI and SRI were increased, 6 months after PRK. Uncorrected vision, best-corrected vision, and predictability decreased, whereas SAI and SRI increased, with increasing attempted correction.
CONCLUSION: PRK, with or without AK, effectively reduced myopia in all eyes by 6 months after surgery. Predictability tended to decrease with increasing attempted correction, even for eyes with relatively low to moderate myopia. PRK may induce surface asymmetry and irregularity at 6 months, and these alterations tend to be greater as the attempted correction increases.

Entities:  

Mesh:

Year:  1998        PMID: 9756445     DOI: 10.1097/00003226-199809000-00008

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Studies of intrastromal corneal ring segments for the correction of low to moderate myopic refractive errors.

Authors:  D J Schanzlin
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Stromal haze, myofibroblasts, and surface irregularity after PRK.

Authors:  Marcelo V Netto; Rajiv R Mohan; Sunilima Sinha; Ajay Sharma; William Dupps; Steven E Wilson
Journal:  Exp Eye Res       Date:  2005-11-21       Impact factor: 3.467

3.  Tissue and cellular biomechanics during corneal wound injury and repair.

Authors:  Vijay Krishna Raghunathan; Sara M Thomasy; Peter Strøm; Bernardo Yañez-Soto; Shaun P Garland; Jasmyne Sermeno; Christopher M Reilly; Christopher J Murphy
Journal:  Acta Biomater       Date:  2017-05-27       Impact factor: 8.947

4.  A novel method for generating corneal haze in anterior stroma of the mouse eye with the excimer laser.

Authors:  Rajiv R Mohan; W Michael Stapleton; Sunilima Sinha; Marcelo V Netto; Steven E Wilson
Journal:  Exp Eye Res       Date:  2007-11-05       Impact factor: 3.467

5.  Analysis of the keratocyte apoptosis, keratocyte proliferation, and myofibroblast transformation responses after photorefractive keratectomy and laser in situ keratomileusis.

Authors:  Steven E Wilson
Journal:  Trans Am Ophthalmol Soc       Date:  2002

6.  Assessment of anti-scarring therapies in ex vivo organ cultured rabbit corneas.

Authors:  Sriniwas Sriram; Daniel J Gibson; Paulette Robinson; Liya Pi; Sonal Tuli; Alfred S Lewin; Gregory Schultz
Journal:  Exp Eye Res       Date:  2014-06-24       Impact factor: 3.467

7.  Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits.

Authors:  Marcelo V Netto; Rajiv R Mohan; Sunilima Sinha; Ajay Sharma; Pankaj C Gupta; Steven E Wilson
Journal:  J Refract Surg       Date:  2006-06       Impact factor: 3.573

8.  Assessment of Corneal Stromal Remodeling and Regeneration after Photorefractive Keratectomy.

Authors:  Pouriska B Kivanany; Kyle C Grose; Madhavi Tippani; Shan Su; W Matthew Petroll
Journal:  Sci Rep       Date:  2018-08-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.